title: Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review.
abstract: OBJECTIVE
  A 1-year systematic review in the field of ocular allergy was carried out to select new information which may be useful for a practical approach to allergic conjunctivitis.
  
  
  RESULTS
  Out of the 56 articles listed by PubMed, 27 papers were included in the review following a consensus achieved among the authors who had independently reviewed all abstracts. Selected articles were classified according to their main focus: antihistamines, omalizumab, new treatments for vernal keratoconjunctivitis and inflammatory ocular disorders, and sublingual immunotherapy.
  
  
  CONCLUSIONS
  The data reviewed are discussed with the aim of underlining unmet needs and making recommendations for future studies on diagnosis and treatment of ocular allergy which may better guide clinical practice in this important area of allergy and clinical immunology.
authors.affiliation: Second University of Naples, Naples, Italy. se.bonini-cnr@flashnet.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Bonini
authors.forename: Claudia
authors.initials: C
authors.lastname: Gramiccioni
authors.forename: Matteo
authors.initials: M
authors.lastname: Bonini
authors.forename: Megon
authors.initials: M
authors.lastname: Bresciani
mesh_terms: D000286:Administration, Sublingual; D018926:Anti-Allergic Agents / Q000276:immunology / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003233:Conjunctivitis, Allergic / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D006634:Histamine H1 Antagonists / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007637:Keratoconjunctivitis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D000069444:Omalizumab
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006634:Histamine H1 Antagonists; D000069444:Omalizumab